De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development
De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development
9 PagesEvaluating novel biotherapeutic drug candidates early through mechanistic modeling is essential for de-risking development pipelines and optimizing molecule design before clinical testing begins. Certara software expertly supports this proactive approach through its comprehensive Early Feasibility Assessment framework and advanced Quantitative Systems Pharmacology Center of Excellence. By utilizing powerful simulation tools, research teams can accurately assess portfolio prioritization, guide the design of complex bispecific antibodies and antibody-drug conjugates, and evaluate half-life extended bio-betters. Ultimately, Certara helps biopharmaceutical organizations answer critical design questions early, eliminate costly experimental dead ends, and successfully accelerate safer, highly ef
